Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy.

[1]  J. Cheville,et al.  The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Cheville,et al.  Diagnosis of prostate cancer in needle biopsies after radiation therapy. , 1999, The American journal of surgical pathology.

[3]  J. Cheville,et al.  Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. , 1999, The American journal of surgical pathology.

[4]  Ximing J. Yang,et al.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? , 1999 .

[5]  F. Vicini,et al.  The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. , 1998, American journal of clinical pathology.

[6]  D. Bostwick,et al.  Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy , 1998, Cancer.

[7]  J. Eble.  Pathology of the Prostate , 1998 .

[8]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  D. Bostwick,et al.  Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. , 1998, Urology.

[10]  J. Epstein,et al.  Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. , 1998, Urology.

[11]  M. Brawer,et al.  Management of radiation failure for localized prostate cancer , 1998, Prostate Cancer and Prostatic Diseases.

[12]  D. Bostwick,et al.  Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. , 1997, The American journal of surgical pathology.

[13]  J. Cheville,et al.  The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. , 1997, American journal of clinical pathology.

[14]  D. Bostwick,et al.  Minimal criteria for the diagnosis of prostate cancer on needle biopsy. , 1997, Annals of diagnostic pathology.

[15]  G. Murphy,et al.  The national cancer data base report on race, age, and region variations in prostate cancer treatment , 1997, Cancer.

[16]  D. Bostwick.  Evaluating prostate needle biopsy: Therapeutic and prognostic importance , 1997, CA: a cancer journal for clinicians.

[17]  S. Piantadosi,et al.  Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. , 1997, The American journal of surgical pathology.

[18]  D. Bostwick,et al.  Stability of the glycoprotein A-80 in prostatic carcinoma subsequent to androgen deprivation therapy. , 1997, The American journal of surgical pathology.

[19]  W. Fair,et al.  Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. , 1997, The Journal of urology.

[20]  D. Bostwick,et al.  The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. , 1997, Human pathology.

[21]  David G. Bostwick,et al.  Urologic Surgical Pathology , 1997 .

[22]  I. Leav,et al.  Androgen Receptor Expression in Prostatic Dysplasia (Prostatic lntraepithelial Neoplasia) in the Human Prostate: An Immunohistochemical and In Situ Hybridization Study , 1996 .

[23]  T. H. van der Kwast,et al.  Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. , 1996, The Journal of urology.

[24]  D. Bostwick,et al.  Molecular biology of prostatic intraepithelial neoplasia , 1996, The Prostate.

[25]  J. Epstein,et al.  Workgroup 5: Assessment of prostate carcinoma in core needle biopsy‐‐Definition of minimal criteria for the diagnosis of cancer in biopsy material , 1996, Cancer.

[26]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[27]  D. Thickman,et al.  Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. , 1996, The Journal of urology.

[28]  D. Bostwick,et al.  Prostate Adenocarcinoma After Androgen Deprivation Therapy: A Comparative Study of Morphology, Morphometry, Immunohistochemistry, and DNA Ploidy , 1996 .

[29]  R. deVere White,et al.  NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. , 1996, The Journal of urology.

[30]  D. Paulson,et al.  p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. , 1996, The Journal of urology.

[31]  D. Tindall,et al.  Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. , 1996, Cancer research.

[32]  R. Montironi,et al.  Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. , 1996, Journal of clinical pathology.

[33]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  C. Magi-Galluzzi,et al.  Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. , 1995, Pathology, research and practice.

[35]  P. Scardino,et al.  High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. , 1995, Pathology, research and practice.

[36]  J. Cheville,et al.  Postatrophic Hyperplasia of the Prostate: A Histologic Mimic of Prostatic Adenocarcinoma , 1995, The American journal of surgical pathology.

[37]  D. Bostwick,et al.  Minimal or No Cancer in Radical Prostatectomy Specimens: Report of 13 Cases of the “Vanishing Cancer Phenomenon” , 1995, The American journal of surgical pathology.

[38]  G. Bianchi,et al.  Total androgenic blockade: a review. , 1995, Acta urologica Belgica.

[39]  H. Scher,et al.  Hormone-refractory (D3) prostate cancer: refining the concept. , 1995, Urology.

[40]  H. Akaza,et al.  Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. , 1995, Journal of the National Cancer Institute.

[41]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[42]  G. Jenster,et al.  Androgen receptor mutations , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  D. Grignon,et al.  Histologic effects of radiation therapy and total androgen blockade on prostate cancer , 1995 .

[44]  A. Hanlon,et al.  External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990 , 1995 .

[45]  V. Speights,et al.  Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients , 1995, Cancer.

[46]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[47]  G. Andriole,et al.  Treatment with finasteride following radical prostatectomy for prostate cancer. , 1995, Urology.

[48]  R. Rittmaster,et al.  Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. , 1995, Endocrinology.

[49]  J. Epstein,et al.  Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. , 1995, Human pathology.

[50]  S. Cohen,et al.  Comparison of the effects of new specific azasteroid inhibitors of steroid 5α‐reductase on canine hyperplastic prostate: Suppression of prostatic DHT correlated with prostate regression , 1995, The Prostate.

[51]  C. Vicentini,et al.  Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. , 1995, Urology.

[52]  P. Troncoso,et al.  Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. , 1994, Urology.

[53]  H. Klocker,et al.  Androgen receptor alterations in prostatic carcinoma , 1994, The Prostate.

[54]  P. Cangh,et al.  Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer , 1994, Clinical endocrinology.

[55]  D. Bostwick.  Grading prostate cancer. , 1994, American journal of clinical pathology.

[56]  C. Cordon-Cardo,et al.  Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma , 1994, The American journal of surgical pathology.

[57]  D. Bostwick,et al.  Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. , 1994, The American journal of surgical pathology.

[58]  D. Bostwick,et al.  Decrease of prostatic intraepithelialneoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy , 1994 .

[59]  D. Wood,et al.  Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. , 1994, Archives of pathology & laboratory medicine.

[60]  S. Plymate,et al.  Effect of 5‐α‐reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC‐3 , 1994, The Prostate.

[61]  E. Round,et al.  CLINICAL-EXPERIENCE OF THE DETECTION OF PROSTATE-CANCER IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH FINASTERIDE , 1994 .

[62]  W. Murphy,et al.  Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone–‐releasing hormone effect). Distinction from poor tumor differentiation , 1994, Cancer.

[63]  D. Bostwick,et al.  Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. , 1993, Human pathology.

[64]  R. Tremblay,et al.  Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs. , 1993, Endocrinology.

[65]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[66]  D. Peters,et al.  Finasteride , 1993, Drugs.

[67]  D. Bostwick,et al.  Atypical Basal Cell Hyperplasia of the Prostate: Immunophenotypic Profile and Proposed Classification of Basal Cell Proliferations , 1993, The American journal of surgical pathology.

[68]  J. Wheeler,et al.  Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression , 1993, Cancer.

[69]  A. Zietman,et al.  Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications , 1993, Cancer.

[70]  J. Montie,et al.  Salvage surgery for radiation failure in prostate cancer , 1993, Cancer.

[71]  M. Soloway,et al.  Antiandrogenic agents as monotherapy in advanced prostatic carcinoma , 1993, Cancer.

[72]  J. Simard,et al.  Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy , 1993, Cancer.

[73]  G. Andriole,et al.  The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.

[74]  D. Siders,et al.  Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. , 1992, Human pathology.

[75]  T. Ahlering,et al.  Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. , 1992, The Journal of urology.

[76]  I. Kaplan,et al.  The importance of local control in the treatment of prostatic cancer. , 1992, The Journal of urology.

[77]  E. Wilson,et al.  Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. , 1992, The Journal of biological chemistry.

[78]  T. Schultheiss,et al.  The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy , 1991, Cancer.

[79]  L. Verhey,et al.  Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. , 1991, The Journal of urology.

[80]  E. Sorkin,et al.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. , 1991, Drugs & aging.

[81]  M. Soloway,et al.  Pathologic changes associated with androgen deprivation therapy for prostate cancer , 1991, Cancer.

[82]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[83]  H. Zincke.  The role of pathologic variables and hormonal treatment after radical prostatectomy for stage D1 disease. , 1991, Oncology.

[84]  J. Srigley,et al.  Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on Normal Prostate and Prostatic Adenocarcinoma: A Histopathologic and Immunohistochemical Study , 1991, The American journal of surgical pathology.

[85]  E. Stoner.  The clinical development of a 5α-reductase inhibitor, finasteride , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[86]  T. Thompson.  Growth factors and oncogenes in prostate cancer. , 1990, Cancer cells.

[87]  C. M. Wilson,et al.  Androgen receptor gene expression in human prostate carcinoma cell lines. , 1990, Cancer research.

[88]  V. Serretta,et al.  Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. , 1989, Urology.

[89]  J. Diamond,et al.  Analysis of independent variables affecting survival after recurrence of prostate cancer. , 1989, International journal of radiation oncology, biology, physics.

[90]  F. Freiha,et al.  Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates , 1989, Cancer.

[91]  J. Srigley,et al.  Clear Cell Cribriform Hyperplasia of Prostate: Report of 10 Cases , 1986, The American journal of surgical pathology.

[92]  S. Mills,et al.  Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens , 1986, Cancer.

[93]  D. Bostwick,et al.  Radiation injury of the normal and neoplastic prostate , 1982, The American journal of surgical pathology.

[94]  Alfred Böcking,et al.  Combined histologic grading of prostatic carcinoma , 1982, Cancer.

[95]  P. Manley,et al.  Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. , 1980, The Journal of urology.

[96]  P. Schellhammer,et al.  Histological characteristics of prostatic biopsies after 125iodine implantation. , 1980, The Journal of urology.

[97]  G. Perry,et al.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma , 1997, Cancer.

[98]  P. Bartels,et al.  Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. A methodological approach. , 1996, European urology.

[99]  J. Goméz,et al.  Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. , 1996, The American journal of surgical pathology.

[100]  J. Oesterling,et al.  The effect of finasteride on prostate specific antigen: review of available data. , 1996, The Journal of urology.

[101]  Bostwick Dg.  Target populations and strategies for chemoprevention trials of prostate cancer. , 1994 .

[102]  V. Steele,et al.  Clinical development plan: Proscar. , 1994, Journal of cellular biochemistry. Supplement.

[103]  I. Kaplan,et al.  Predictors of survival after a positive post-irradiation prostate biopsy. , 1994, International journal of radiation oncology, biology, physics.

[104]  A. Kaisary,et al.  Current clinical studies with a new nonsteroidal antiandrogen, casodex , 1994, The Prostate. Supplement.

[105]  J. Trachtenberg,et al.  Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. , 1993, European urology.

[106]  C. Busch,et al.  Histopathological changes in androgen-deprived localized prostatic cancer. A study in total prostatectomy specimens. , 1993, European urology.

[107]  D. Kuban,et al.  Prognostic significance of post-irradiation prostate biopsies. , 1993, Oncology.

[108]  I. Kaplan,et al.  The clinical significance of a positive post-irradiation prostatic biopsy without metastases. , 1992, International journal of radiation oncology, biology, physics.

[109]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657 , 1992 .

[110]  C. Vicentini,et al.  Antiandrogens and 5-alpha reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell lines , 1992 .

[111]  D L McShan,et al.  Boost treatment of the prostate using shaped, fixed fields. , 1989, International journal of radiation oncology, biology, physics.

[112]  F. Labrie,et al.  New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens , 1983, The Prostate.